MedTrace Logo

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

NCT00590395 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-12-10

Study results available
· View outcomes & findings →

Summary

This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or inflammation of the gallbladder.

Conditions

  • Cholecystitis

Interventions

DRUG

18FDG (an FDA-approved radiopharmaceutical)

Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration

Sponsors & Collaborators

  • Alan D. Waxman, M.D.

    lead OTHER

Principal Investigators

  • Alan D. Waxman, M.D. · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-01-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00590395 on ClinicalTrials.gov